Back to Results

Esperion Therapeutics Inc (ESPR)

Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for adults with elevated LDL cholesterol in the United States. Its marketed portfolio includes NEXLETOL and NEXLIZET, oral once-daily non-statin tablets used in patients with primary hyperlipidemia, including those with heterozygous familial hypercholesterolemia and cardiovascular disease who need additional LDL-C reduction. The company also markets NILEMDO, an ACL inhibitor, and NUSTENDI, a bempedoic acid and ezetimibe tablet for elevated LDL-C. Esperion has collaboration and license agreements with Daiichi Sankyo Co. Ltd., Otsuka Pharmaceutical Co., Ltd., and Daiichi Sankyo Europe GmbH. Incorporated in 2008 and formerly known as HDL Therapeutics, Inc., the company is headquartered in Ann Arbor, Michigan.


Stock Summary Fair Value Profitability & Growth Quality & Risk Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Price-to-Sales Ratio Market Cap Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-ESPR
Not available
Not available
Not available
Great
2.0x
819.5 M
39.9%
91.0%
-2.5
247.6%
Valuation • Fair Value

Esperion Therapeutics Inc (NASDAQ-ESPR) Fair Value by Valuation Model

No usable valuation estimate is currently available for Esperion Therapeutics Inc (NASDAQ-ESPR); fair value and analyst target coverage statuses are shown explicitly below.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

No usable valuation estimate is currently available for Esperion Therapeutics Inc (NASDAQ-ESPR). Fair value and the analyst target remain visible as coverage-status fields and should not be read as valuation signals while unavailable.

Profitability • Growth

Profitability & Growth for Esperion Therapeutics Inc (NASDAQ-ESPR)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

418.2 M

Current operating scale indicator.

Revenue Forecast

362.7 M

Forward revenue estimate.

EBITDA

75.894 M

Current operating profitability reference.

EBITDA Forecast

86.461 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Esperion Therapeutics Inc (NASDAQ-ESPR) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Esperion Therapeutics Inc (NASDAQ-ESPR)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-1.94

Intermediate zone that deserves monitoring.

Altman Z-Score

-2.5

Lower score that deserves closer risk review.

FCF / Net Income

247.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Esperion Therapeutics Inc (NASDAQ-ESPR). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Esperion Therapeutics Inc (NASDAQ-ESPR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Esperion Therapeutics Inc (NASDAQ-ESPR) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Esperion Therapeutics Inc (NASDAQ-ESPR) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Esperion Therapeutics Inc (NASDAQ-ESPR) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Buy

The monthly technical read for Esperion Therapeutics Inc (NASDAQ-ESPR) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Esperion Therapeutics Inc (NASDAQ-ESPR) Stock FAQ

Data-supported answers about Esperion Therapeutics Inc (NASDAQ-ESPR), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
Not available
No reliable estimate from the currently supported inputs
Financial Health
Great
Current financial-health read

A reliable fair value estimate is not currently available for Esperion Therapeutics Inc (NASDAQ-ESPR). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

The current financial health read for Esperion Therapeutics Inc (NASDAQ-ESPR) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The current market capitalization listed for Esperion Therapeutics Inc is 819.5 M.

The ticker symbol for Esperion Therapeutics Inc is NASDAQ-ESPR, and the stock is listed on NASDAQ.

Esperion Therapeutics Inc (NASDAQ-ESPR) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Esperion Therapeutics Inc is 39.9%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Esperion Therapeutics Inc is 91.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B